Please assess the completion status of the following clinical trial:

Trial Title: A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed or refractory Hodgkin lymphoma who have previously received autologous stem cell transplant.~* Histologically confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.~* Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease of at least 1.5 cm as documented by spiral computed tomography.~* At US sites patients greater than or equal to 12 years of age may be enrolled. At non-US sites patients must be greater than or equal to 18 years of age.~Exclusion Criteria:~* Previous treatment with brentuximab vedotin.~* Previously received an allogeneic transplant.~* Congestive heart failure, Class III or IV, by the New York Heart Association criteria.~* History of another primary malignancy that has not been in remission for at least 3 years.~* Known cerebral/meningeal disease.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).